Please enable Javascript
Prostate Cancer Diagnostics
Advertisement
Clarity Pharmaceuticals’ COBRA Study Selected as Top-Rated Oral Presentation at EANM 2024
Brandon Twyford
Prostate Cancer Diagnostics
|
October 2, 2024
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Read More
PEACE-1: Identifying Prognostic and Predictive Biomarkers for SOC Treatment of mCSPC
Cedric Pobel, MD
mCSPC
|
September 26, 2024
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
View More
Phenotypic Biomarker Characterization in de Novo Metastatic Prostate Cancer
Jordana Jampel
mCSPC
|
September 11, 2024
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Read More
FDA Grants Fast Track Designation to 64Cu-SAR-bisPSMA
Katy Marshall
Prostate Cancer Diagnostics
|
August 26, 2024
A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR.
Read More
CLARIFY: Phase 3 Diagnostic Trial of 64Cu-SAR-bisPSMA PET Imaging in Prostate Cancer Before Surgery
Brian Helfand, MD, PhD
Prostate Cancer Diagnostics
|
August 20, 2024
Dr. Helfand explores the potential of Clarity's 64Cu-SAR-bisPSMA agent for prostate cancer imaging.
View More
Evaluating 18F-Flotufolastat in Black Patients With Prostate Cancer Recurrence
Katy Marshall
Prostate Cancer Diagnostics
|
August 19, 2024
Black patients are often under-represented in oncology clinical trials.
Read More
Stockholm3 Blood Test Reduces Unnecessary Prostate Biopsies in Diverse Patient Populations
Emily Menendez
Prostate Cancer Diagnostics
|
August 19, 2024
Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates.
Read More
Staging Intermediate- and High-risk Prostate Cancer With 18F PSMA/PET/CT vs MRI
Adam Kinnaird, MD, PhD
Prostate Cancer Diagnostics
|
August 12, 2024
Dr. Kinnaird elaborates on some of the limitations of MRI and benefits of PET/CT staging for locoregional prostate cancer.
View More
18F-PSMA-1007 PET/CT Versus MRI in Locoregional, High-Risk Prostate Cancer Staging
Emily Menendez
Prostate Cancer Diagnostics
|
August 2, 2024
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
Read More
FDA Accepts New Drug Application for Prostate Cancer Imaging Agent
Zachary Bessette
Prostate Cancer Diagnostics
|
July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Read More
Gleason Grade Group 1 Prostate Cancer May Still Carry Risk of Mortality
Emily Menendez
Prostate Cancer Diagnostics
|
August 2, 2024
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Read More
Connection Between Genetic Risk, Early Death Among Patients With Prostate Cancer
Katy Marshall
Prostate Cancer Diagnostics
|
August 2, 2024
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Read More
AI Systems as Supportive Tools for Detecting Clinically Significant Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
August 2, 2024
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
Read More
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
View More
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
View More
18F-rhPSMA-7 Versus Conventional Salvage Radiotherapy for BCR
Zachary Bessette
Prostate Cancer Diagnostics
|
June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Read More
COBRA Study Highlights Efficacy of 64Cu-SAR-bisPSMA for Detecting Recurrent Prostate Cancer
Brandon Twyford
Prostate Cancer Diagnostics
|
June 11, 2024
COBRA trial shows 64Cu-SAR-bisPSMA improves detection of recurrent prostate cancer with high specificity.
Read More
Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging
Tian Zhang, MD
Prostate Cancer Diagnostics
|
June 10, 2024
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
View More
Evaluating Salvage Radiotherapy Field, Risk Factors in Prostate Cancer Recurrence
Katy Marshall
Prostate Cancer Diagnostics
|
May 21, 2024
Researchers found no differences between the proportion of distant metastases in the salvage PBRT and WPRT groups.
Read More
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy
Eric Li, MD
Prostate Cancer Diagnostics
|
May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
View More
Load More
Advertisement
Advertisement
Advertisement